Physician profile
Michael J Bohn
NPI 1962411686
$441.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.36 · 2020: $246 · 2021: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $134.61 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $128.99 | 2020-2021 | |
| Lundbeck LLC | $49.45 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $32.06 | 2019 | |
| Neurocrine Biosciences, INC. | $18.46 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.43 | 2019 | |
| Gilead Sciences, INC. | $17.25 | 2020 | |
| Abbvie INC. | $15.55 | 2021 | |
| Alkermes, INC. | $14.01 | 2020 | |
| Noven Therapeutics, LLC | $13.04 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.